Segment Reporting

6 Months Ended

Jun. 30, 2020

Segment Reporting [Abstract]

Segment Reporting

13.   Segment Reporting. We report our operations in two operating segments: cardiovascular and endoscopy. Our cardiovascular segment consists of four product categories: peripheral intervention, cardiac intervention, custom procedural solutions, and OEM. Within these product categories, we sell a variety of products, including cardiology and radiology devices (which assist in diagnosing and treating coronary arterial disease, peripheral vascular disease and other non-vascular diseases), as well as embolotherapeutic, cardiac rhythm management, electrophysiology, critical care, breast cancer localization and guidance, biopsy, and interventional oncology and spine devices. Our endoscopy segment consists of gastroenterology and pulmonology devices which assist in the palliative treatment of expanding esophageal, tracheobronchial and biliary strictures caused by malignant tumors. We evaluate the performance of our operating segments based on net sales and operating income.

Financial information relating to our reportable operating segments and reconciliations to the consolidated totals for the three and six-month periods ended June 30, 2020 and 2019, were as follows (in thousands):

	Three Months Ended				Six Months Ended
	June 30,				June 30,
	2020		2019		2020		2019
Net Sales
Cardiovascular	$	212,177	$	246,666	$	447,721	$	477,146
Endoscopy		6,194		8,866		14,175		16,735
Total net sales		218,371		255,532		461,896		493,881
Operating Income (Loss)
Cardiovascular		(20,462)		9,855		(18,960)		17,474
Endoscopy		1,467		2,346		1,327		4,250
Total operating income (loss)		(18,995)		12,201		(17,633)		21,724
Total other expense - net		(3,305)		(3,202)		(6,659)		(5,879)
Income tax (benefit) expense		(3,242)		2,140		(2,080)		2,791
Net income (loss)	$	(19,058)	$	6,859	$	(22,212)	$	13,054